Which items should be monitored monthly in a patient taking clozapine?

• A. Only CBC
• B. Just liver enzymes
• C. ANC/WBC counts, metabolic panel, weight/BMI, and vital signs
• D. None

Answer: (C)

Clozapine requires active, comprehensive safety monitoring because it carries several serious risks that can emerge even with multiple doses. The monthly checks should include ANC/WBC counts, a metabolic panel, weight/BMI, and vital signs.

ANC/WBC counts are essential to catch agranulocytosis early, a potentially life-threatening drop in white blood cells that clozapine can cause. Regular monitoring of these values helps catch neutropenia before infections develop and guides decisions about continuing or stopping the medication.

A metabolic panel is important because clozapine can affect metabolic processes and organ function. It assesses liver enzymes, kidney function, electrolytes, and other markers that can signal adverse effects or complications, including metabolic disturbances that the drug can promote.

Tracking weight and BMI highlights metabolic risk over time, since weight gain and related issues like insulin resistance and dyslipidemia are common with clozapine and require lifestyle or medical interventions.

Vital signs provide a window into cardiovascular and overall health. They help detect early signs of myocarditis, hypertension, tachycardia, or other instability that could be related to the drug or its interactions.

Choosing to monitor only a single parameter—such as just CBC or just liver enzymes—misses other important safety domains. Since clozapine poses hematologic, metabolic, hepatic, and cardiovascular risks, a comprehensive, monthly approach covering these areas best protects the patient.